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Abstract
Objective
To test the ability of the Ages and Stages Questionnaire, Third Edition (ASQ3) to help iden-
tify or exclude neurodevelopmental impairment (NDI) in very preterm-born children at the
corrected age of two.
Methods
We studied the test results of 224 children, born at <32 postmenstrual weeks, who had
scores on ASQ3 and Bayley Scales of Infant and Toddler Development, Third Edition (BSI-
DIII) and neurological examination at 22–26 months’ corrected age. We defined NDI as a
score of <70 on the cognitive—or motor composite scale of BSIDIII, or impairment on neuro-
logical examination or audiovisual screening. We compared NDI with abnormal ASQ3
scores, i.e., < -2SDs on any domain, and with ASQ3 total scores. To correct for possible
overestimation of BSIDIII, we also analyzed the adjusted BSIDIII thresholds for NDI, i.e.,
scores <80 and <85.
Results
We found 61 (27%) children with abnormal ASQ3 scores, and 10 (4.5%) children who had
NDI with original BSIDIII thresholds (<70). Twelve children had NDI at BSIDIII thresholds at
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<80, and 15 had <85. None of the 163 (73%) children who passed ASQ3 had NDI. The sen-
sitivity of ASQ3 to detect NDI was excellent (100%), its specificity was acceptable (76%),
and its negative predictive value (NPV) was 100%. Sensitivity and NPV remained high with
the adjusted BSIDIII thresholds.
Conclusion
The Ages and Stages Questionnaire is a simple, valid and cost-effective screening tool to
help identify and exclude NDI in very preterm-born children at the corrected age of two
years.
Introduction
Identifying neurodevelopmental impairment (NDI) at a young age is important for children at
risk for developmental problems, brought on by preterm birth or neonatal encephalopathy.
Early recognition of NDI is one of the key recommendations of the American Academy of
Pediatrics [1]. It improves the chances of early intervention within the windows of opportunity
for development [2,3].
The standardized tool used most frequently to assess development at a young age is the Bay-
ley Scales of Infant and Toddler Development (BSID). This tool is often referred to as the gold
standard for infant development and is used in structured follow-up care of and in research on
very preterm-born children and other high risk groups [4]. A practical disadvantage, however,
is that it is laborious and costly. It takes approximately 50 to 90 minutes to complete and it
must be administered by trained professionals. Furthermore, it requires a fully cooperative
child who has sufficient neurosensory skills [5].
Neurodevelopmental outcome is usually expressed as rates of NDI, whereby sensory
impairment and neurological dysfunction leading to cerebral palsy are scored independently
and added to BSID scores below -2SD [6,7].
If the purpose of neurodevelopmental testing is to identify or exclude NDI, then using pro-
fessional-completed or parent-completed developmental screeners may be less time consuming
and more cost-effective [8]. Currently, the most widely used parent-completed questionnaires
for young children is the Ages and Stages Questionnaire (ASQ) [9]. ASQ has shown high
sensitivity and specificity for detecting developmental delay [10–13]. Earlier, the ASQ, Second
Edition (ASQ2) had been compared to BSID Second Edition (BSIDII) with promising results
[10–12]. Recently, the ASQ, Third Edition (ASQ3) was compared with BSIDIII in a mixed
term-born and preterm-born population of children aged 8, 18, and 30 months, yielding ade-
quate sensitivity and specificity [13]. To our knowledge, the ASQ3-24 month’s version has not
been compared to BSIDIII or to formal NDI assessments at 24 months’ corrected age, even
though NDI at 24 months is an important end-point in many clinical studies.
The objective of our study was to test the ability of the ASQ3 24 months’ version to correctly
identify or exclude NDI in very preterm-born children at the age of two.
Methods
Population and participants
Participants were two-year-old children who were born preterm at< 32 weeks’ postmenstrual
age, without major congenital abnormalities, and who had been treated in one of the ten
ASQ and Neurodevelopmental Impairment
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tertiary Neonatal Intensive Care Units (NICU’s) in the Netherlands. These children were ini-
tially recruited as part of the BARTrial (ISRCTN74465643), a prospective, randomized con-
trolled, multicenter study that aimed to reduce bilirubin induced neurological dysfunction
[14–15]. A total of 301 survivors for whom we had results on BSIDIII and the complete neuro-
logical and sensory examinations, and whose parents had completed the ASQ3 within a time
window of 2 months (22–26 months), were included in this part of the study. The Medical
Ethics Review Board of University Medical Center Groningen approved the study. Written
informed consent was obtained from the parents or legal guardian of each participating infant.
This study was conducted according to the principles expressed in the Declaration of Helsinki.
Measures
The Ages and Stages Questionnaire (ASQ) is a parent-completed screening tool [9]. It mea-
sures developmental milestones in five domains (communication, fine motor, gross motor,
problem solving ability, and personal-social functioning). Each domain consists of six ques-
tions. Parents indicate whether their child has mastered the milestone (yes, 10 points), partly/
inconsistently (partly, 5 points), or not yet (no, 0 points). The ASQ2 was translated into Dutch
(Dutch-ASQ) and back-translated once prior to the study to check for problems relating to the
translation [16]. Pending the Dutch ASQ norms, we used the original United States (U.S.)
ASQ3 cut-off norms that had been generated from a large standardized sample of American
children. We chose to use the ASQ3 norms for the Dutch-ASQ because to all intents and pur-
poses the domain items of the original English ASQ2 and ASQ3 24 months versions are the
same except for some minor alterations in the English wording of the questions. We defined
“failing ASQ3”, which indicates possible developmental delay, as a score of more than 2 SDs
below the mean score for the U.S. reference group (ASQ3) on any of the five domains, or a
domain with an invalid score due to more than two missing answers on that domain, both in
accordance with the manual [9].
The Bayley Scales of Infant and Toddler Development, Third Edition (BSIDIII), is a widely
used tool to assess development of infants and toddlers from 0.5 to 42.5 months of age [4,5].
It quantifies cognitive, language, and motor skills through a series of standardized test items
and social and adaptive skills through parental questionnaires. In 2000, the normative data
of BSIDIII were generated from a standardization sample of more than 1400 American chil-
dren aged 1 to 42 months [5]. BSIDIII provides five norm-referenced composite scores (cogni-
tive, language, motor, social and adaptive) with a mean of 100 and a SD of ±15. The original
U.S. cut-off scores for delay on BSIDIII were set at -2SDs (i.e at 70) in accordance with the orig-
inal manual. In this study we assessed the cognitive and composite motor score of BSIDIII, in
analogy to its two predecessors of BSIDII: the mental development index (MDI) and the psy-
chomotor development index (PDI) [17]. Due to increasing concerns about possible overesti-
mation of BSIDIII cognitive and motor scales in comparison to BSIDII [18–20], we also
examined additional cut-off composite scores for the BSIDIII<80 and<85, hereafter referred
to as “adjusted” BSIDIII thresholds, in accordance with current recommendations [19–20].
We defined neurodevelopmental impairment (NDI) as either a BSIDIII cognitive score or
composite motor score of< 70, moderate or severe cerebral palsy according to neurological
examination [21], or a score> II on the Gross Motor Function Classification System
(GMFCS) [22], bilateral blindness (visual acuity of<20/200), or bilateral deafness (bilateral
hearing loss of>40 dB). For the “adjusted” NDI assessments, cut-off scores for BSIDIII were
raised to<80 and<85, respectively, whereby the other outcome measures remained
unchanged.
ASQ and Neurodevelopmental Impairment
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Procedures
Parents received the Dutch-ASQ at home together with an invitation for this part of the study
a few weeks before to the planned follow-up visit. During this visit a trained professional
administered the BSIDIII cognitive and motor scales, conducted an age appropriate examina-
tion, including a neurological examination according to Touwen [23], and did visual and hear-
ing assessments. In addition, we collected medical data concerning gestational age, small for
gestational age (SGA) status (<P10) [24] and information about medical complications before
discharge.
The Dutch-ASQ forms were collected during the visit. If parents had not yet completed the
questionnaire, they were reminded once or twice by telephone afterwards. The professionals
who administered BSIDIII were blind as to the ASQ results. A time window for the Dutch-
ASQ was set at two months around the second birthday (22 to 26 months) corrected for gesta-
tional age in accordance with the guidelines in the most recent ASQ manual [9]. BSIDIII results
were analyzed for all children with BSIDIII results within the range of 21 to 30 months’ cor-
rected age.
Statistical analyses
We calculated percentages for children with abnormal ASQ scores for different demographic
variables and biological risk factors. The differences in percentages of abnormal ASQ results
for children with and without risk factors were tested with chi-square analyses. We cross-tabu-
lated the results on the ASQ3 and BSIDIII and calculated sensitivity, specificity, positive pre-
dictive value (PPV) and negative predictive values (NPV) for NDI at original and adjusted
thresholds. Furthermore we added up all ASQ domain scores to form an ASQ total score and
compared this to the additive BSID cognitive and composite motor scores using linear regres-
sion analysis and receiver operator characteristics. Incomplete BSID scores due to CP or severe
mental impairment were imputed at 50 and incomplete ASQ scores were imputed with 0
points per item without a valid score. We investigated on which ASQ3 domains the very-pre-
term children failed most often, both overall as well as for children with and without NDI. Sta-
tistical analyses were performed with SPSS version 19 (SPSS Inc., Chicago, Il, USA). Statistical
significance was preset at P< 0.05.
Results
Out of a total of 301 eligible children, 261 (87%) had results within the time windows of ASQ3
and BSIDIII. Data on 37 children were incomplete so that we were unable to determine NDI
and ASQ scores in 25 and 12 cases, respectively. Eventually, we compared ASQ3 scores and
NDI results of 224 (74%) out of 301 children (Fig 1). The characteristics of these children are
described in Table 1. Children who were excluded did not differ significantly from the other
participants on demographic characteristics, BSIDIII results, or rates of NDI (S1 Table). The
mean age at assessment was 24 months for both ASQ3 and BSIDIII.
Out of 224 children 61(27%) had abnormal ASQ3 scores and 10 (4.5%) had NDI, using
original cut-off scores for BSIDIII at -2SDs (<70) (Table 2). Significantly more children with a
gestational age of<28 weeks failed ASQ3. Children who were part of a multiple birth, or who
had intraventricular hemorrhage (IVH) or periventricular leukomalacia (PVL)>grade 2, or
bronchopulmonary dysplasia (BPD), also failed ASQ3 more often.
There were 10 (4.5%) children with NDI at the original BSIDIII cut-off thresholds of<70,
12 (5.4%) with an adjusted threshold of<80, and 15 (7.0%) with an adjusted threshold of<85
(Table 3 and S2 Table). Sensitivity at the original thresholds for the BSIDIII to detect NDI
was 100% and specificity 76%. The negative predictive value (NPV) was 100% and positive
ASQ and Neurodevelopmental Impairment
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Fig 1. Flowchart with numbers of eligible and included children. ASQ3; Ages and Stages Questionnaire, Third Edition, time window 22–26 months
corrected age. BSIDIII: Bayley Scales of Infant and Toddler Development, Third Edition, time window 21–30 months corrected age. NDI:
Neurodevelopmental Impairment: BSIDIII cognitive score or composite motor score <70, bilateral blindness/deafness or cerebral palsy.
doi:10.1371/journal.pone.0133087.g001
Table 1. Characteristics of the study sample.
Characteristic N = 224
Gestational age in weeks 29.3 ± 1.9 [24–31]
Birth weight in grams 1270 ± 337 [600–2300]
Age of assessment ASQ3 in months 24 ± 0.98 [22–26]
Age of assessment BSIDIII in months 24 ± 1.19 [22–30]
Total ASQ3 score 250 (225–270)
BSIDIII cognitive score 100 (95–110)
BSIDIII composite motor score 100 (94–110)
Data are expressed as mean ± SD and [range], or median and (25–75 percentile)
ASQ3: Ages and Stages Questionnaire, Third Edition
BSIDIII: Bayley Scales of Infant and Toddler Development, Third Edition
doi:10.1371/journal.pone.0133087.t001
ASQ and Neurodevelopmental Impairment
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predictive value (PPV) 16%. With adjusted composite score thresholds at<80 and<85 for
BSIDIII, ASQ3 correctly identified 12 out of 12 and 13 out of 15 children with NDI; sensitivity
and NPV remained high. These figures were not essentially different in the subgroup of chil-
dren born before 28 weeks of gestation (S3 Table).
Fig 2 shows the significant correlation between ASQ-total scores and combined BSID
scores, with a relatively wide range (R-square is 0.43, p<0.001). A cut-off for the ASQ total
score below 188 led to a sensitivity of 96% with a specificity of 90% to detect NDI with a BSI-
DIII threshold set at< 70, area under the curve in the ROC curve (Fig 3) was 96% (p<0.0001).
Fig 4 shows the ranges in total ASQ scores for children with NDI and those without NDI
(No-NDI), p<0.001. Children who passed ASQ3 had significantly higher cognitive scores and
composite motor scores than children who failed ASQ3 (P<0.001), and who failed the ASQ
without NDI (P<0.001) (S4 Table).
Table 2. Characteristics of children who failed the ASQ3 or had NDI.
All Failure ASQ3 NDI
N = 224 n = 61 n = 10
Characteristic n n (%) P n (%) P
Gestational age < 28 weeks 61 25 (41) 0.005 4 (7) 0.353
>28weeks 163 36 (22) 6 (4)
SGA1 <P10 45 12 (27) 0.924 1 (2) 0.415
>P10 179 49 (27) 9 (5)
Gender Male 122 37 (30) 0.255 7 (6) 0.313
Female 102 24 (24) 3 (3)
Multiple birth Multiple 71 27 (38) 0.013 5 (7) 0.203
Single 153 34 (22) 5 (3)
Ethnicity mother n = 221 Caucasian 206 57 (28) 0.933 10 (5) 0.382
Non-Caus. 15 4 (27) 0 (0)
Education mother2 n = 208 Low 28 7 (25) 0.670 0 (0) 0.226
Middle/high 180 52 (29) 9 (5)
NEC Yes 9 3 (33) 0.675 1 (11) 0.324
No 215 58 (27) 9 (4)
IVH or PVL3 Yes 13 8 (62) 0.004 0 (0) 0.422
No 211 53 (23) 10 (5)
BPD4 Yes 24 11 (46) 0.030 1 (4) 0.940
No 200 50 (25) 9 (5)
Sepsis5 Yes 5 3 (60) 0.096 1 (20) 0.089
No 219 58 (27) 9 (4)
Data are presented as numbers (N, n), percentages (%) of children with abnormal ASQ3 scores and NDI and P-values in chi-square analyses. N = 224
unless stated otherwise, ASQ3: Ages and Stages Questionnaire, Third Edition, BSIDIII: Bayley Scales of Infant and Toddler Development, Third Edition.
NDI: neurodevelopmental impairment: BSIDIII cognitive score or composite motor score of <70, bilateral blindness/deafness or cerebral palsy. Failure
ASQ3: a score of >2 SD below the mean score for the US reference group on any domain.
1 SGA: small for gestational age, birth weight < P10 on Dutch reference growth chart.
2 low education of mother is less than 5 years high school education.
NEC is necrotizing enterocolitis
3 IVH or PVL: intraventricular hemorrhage  grade 3 (Papile) or periventricular leukomalacia  grade 3. (De Vries)
4 BPD: bronchopulmonary dysplasia deﬁned as oxygen dependence at 36 weeks’ gestation.
5 Sepsis: clinical signs of septicemia and positive blood culture.
doi:10.1371/journal.pone.0133087.t002
ASQ and Neurodevelopmental Impairment
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More than half, i.e. 34 out of 61 (56%) children with abnormal ASQ3 results, failed on the
gross motor domain (Table 4), and 18 (30%) failed on the communication domain; 12 of them
(25%) had no NDI (S5 Table). Eighty percent of the children with NDI failed on more than
one ASQ3 domain.
When using ASQ2 thresholds the same 61 children plus an additional number of 23 chil-
dren had abnormal results: sensitivity remained 100% while specificity dropped to 65%.
Discussion
This study demonstrated excellent sensitivity and acceptable specificity of ASQ3 to detect NDI
in very preterm born children at the corrected age of two years, within the ranges of original
and adjusted BSIDIII cut-off scores. The negative predictive value was 100%, which indicates
that ASQ3 can be used confidently to screen for NDI. Using ASQ3 and only referring those
children with abnormal ASQ results for further testing would reduce the number of children
who have to undergo extensive neurodevelopmental testing, thus thoroughly reducing the
costs involved in such programs.
Furthermore, the children with ASQ3 failure without NDI had significantly lower BSIDIII
scores also, which strengthens the potential use of ASQ as children with borderline BSIDIII
scores might benefit from closer follow-up or serial ASQ surveillance.
Our results were in agreement with several other studies that tested the ability of ASQ to
detect neurodevelopmental delay despite varying populations, ages of assessment, NDI thresh-
old definitions, and various gold standard tests [10–12,25,26]. The heterogeneity of these stud-
ies limits comparability but also supports a broad applicability of ASQ3. Moreover, most of
these studies analyzed ASQ2. Our results showed that using ASQ3 thresholds resulted in higher
specificity without reducing sensitivity.
Table 3. ASQ3 versus NDI with original (<70) and adjusted BSID thresholds (<80 and <85), sensitivity,
specificity, negative and positive predictive values.
NDI with
BSIDIII<70
NDI with
BSIDIII<80
NDI with
BSIDIII<85
Yes No Yes No Yes No
Failure ASQ3 (n = 61) 10 51 12 49 13 48
Normal ASQ3 (n = 163) 0 163 0 163 2 161
Total (N = 224) 10 214 12 212 15 209
Sensitivity 100% (10/10) 100% (12/12) 87% (13/15)
Speciﬁcity 76 (163/214) 77% (163/212) 77% (161/209)
Negative Predictive Value 100% (163/163) 100% (163/163) 99% (161/163)
Positive Predictive Value 16% (10/61) 20% (12/61) 21% (13/61)
Data are presented as numbers and percentages.
ASQ3: Ages and Stages Questionnaire, Third edition.
Failure ASQ3: a score of >-2 SD below the mean score for the U.S. reference group on any domain
BSIDIII: Bayley Scales of Infant and Toddler Development, Third Edition.
NDI with BSIDIII<70: neurodevelopmental impairment with BSIDIII cognitive score or composite motor
score of <70, bilateral blindness/deafness and/or cerebral palsy.
NDI with BSIDIII<80: neurodevelopmental impairment with BSIDIII cognitive score or composite motor
score of <80, bilateral blindness/deafness and/or cerebral palsy.
NDI with BSIDIII< 85: neurodevelopmental impairment with BSIDIII cognitive score or composite motor
score of <85, bilateral blindness/deafness and/or cerebral palsy.
doi:10.1371/journal.pone.0133087.t003
ASQ and Neurodevelopmental Impairment
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To our knowledge, one study compared the new ASQ3 with BSIDIII at 8, 18 and 30 months,
with the threshold set at -1SD on at least one domain [13]. It reported an overall sensitivity
of 75% and a specificity of 81% in 306 term-born and preterm-born children. The psychomet-
ric properties were better for preterm-born children than term-born children and at more
advanced test ages. Our study elaborated on these results by adding an important age of assess-
ment, i.e. 24 months, using NDI as outcome measure instead of BSID scores only, and proved
ASQ3 thresholds to have better specificity than ASQ2 thresholds. Additionally, we studied a
large number of children at one time-point, and we also analyzed two additional thresholds on
BSIDIII for NDI. We did so in response to growing concern regarding the differences in test
scores of BSIDIII compared to BSIDII [18–20,27,28]. The reasons for the differences, and the
question whether the BSIDII underestimates or whether BSIDIII overestimates the outcomes
of the children, remain unclear. The BSIDIII administration manual [5] states that both the
cognitive score and the composite motor scores are 7 points higher than the MDI and PDI of
BSIDII. A possible explanation might be the difference in norm groups, with more mildly
impaired children (10%) and proportionally more Hispanic Americans (16%) in the reference
Fig 2. Correlation between BSIDIII combined cognitive and composite motor scores and ASQ3 total scores.R square is 0.417, p<0.001. Incomplete
BSID scores due to CP or severe mental impairment were imputed at 50 and incomplete ASQ scores were imputed with 0 points per item without a valid
score.
doi:10.1371/journal.pone.0133087.g002
ASQ and Neurodevelopmental Impairment
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group of the BSIDIII in comparison to BSIDII [29]. Several groups found larger mean differ-
ences (8 to 15 points), especially in the lower-end scores on several BSIDIII scales compared to
BSIDII, with a non-linear correlation [18–20,27,28,31].
We chose<80 and<85 as additional thresholds for the cognitive and composite motor
score to define NDI as was suggested by several of these authors [19,20,30,31].
Regardless of exact thresholds on BSIDIII, the question remains whether developmental
screening tools can be used reliably to detect which children in high-risk groups should be
referred for more in-depth neurodevelopmental assessment. If the aim is to detect NDI, such a
screening would reduce workload and would relieve the financial burden of large scale follow-
up programs. About three out of four children in this study would have been identified as
developing according the norm, without formal developmental testing. Even after applying the
adjusted thresholds for the BSIDIII (threshold BSID<85), the workload of testing an addi-
tional 163 children to detect two more children with NDI is huge. Depending on the reason for
assessment, the available resources, and other possible safety nets to ensure that early identifi-
cation of children at risk of developmental impairment is guaranteed, this may or may not be
Fig 3. ROC curve for NDI with BSIDIII threshold< 70 versus ASQ3 total scores. Area under the curve 96% p<0.0001
doi:10.1371/journal.pone.0133087.g003
ASQ and Neurodevelopmental Impairment
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Fig 4. ASQ3 total scores for children with No NDI and children with NDI. NDI with BSID threshold set at < 70. Incomplete BSIDIII scores due to CP or
severe mental impairment were imputed at 50 and incomplete ASQ3 scores were imputed with 0 points per item without a valid score.**** p< 0.0001
doi:10.1371/journal.pone.0133087.g004
Table 4. ASQ3 failures and the domains for different NDI thresholds.
NDI with BSIDIII<70 NDI with BSIDIII<80 NDI with BSIDIII<85 Total
n = 10 n = 12 n = 15 N = 224
Failure ASQ3 10 (100%) 12 (100%) 13 (87%) 61 (27%)
Domain ASQ3 Failure n (%) Failure n (%) Failure n (%) Failure n (%)
Communication 6 (60%) 6 (50%) 6 (40%) 18 (8%)
Gross Motor 8 (80%) 9 (75%) 9 (60%) 34 (15%)
Fine Motor 3 (30%) 5 (42%) 5 (33%) 12 (5%)
Problem Solving 7 (70%) 7 (58%) 7 (47%) 14 (6%)
Personal Social 6 (60%) 6 (50%) 7 (47%) 18 (8%)
Data are presented as numbers and percentages.
ASQ3: Ages and Stages Questionnaire, Third edition.
Failure ASQ3: a score of >2 SD below the mean score for the U.S. reference group on any domain
BSIDIII: Bayley Scales of Infant and Toddler Development, Third Edition.
NDI with BSIDIII<70: neurodevelopmental impairment with BSIDIII cognitive score or composite motor score of <70, bilateral blindness/deafness and/or
cerebral palsy.
NDI with BSIDIII<80: neurodevelopmental impairment with BSIDIII cognitive score or composite motor score of <80, bilateral blindness/deafness and/or
cerebral palsy.
NDI with BSIDIII<85: neurodevelopmental impairment with BSIDIII cognitive score or composite motor score of <85, bilateral blindness/deafness and/or
cerebral palsy.
doi:10.1371/journal.pone.0133087.t004
ASQ and Neurodevelopmental Impairment
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considered acceptable. Furthermore, administering serial ASQ’s at different points in time, or
administering an ASQ of a more advanced age than the corrected age (e.g. calendar age) of the
child in order to improve sensitivity, or combining ASQ results with other know risk factors
such as intraventricular hemorrhage, periventricular leucomalacia, retinopathy and broncho-
pulmonary dysplasia might further improve these figures, and may help to identify early pre-
term born children who are at risk for NDI at a younger age [32].
The major strength of our study was using NDI as an indicator of developmental delay, not
relying only on BSIDIII test results because several children failed on the neurological or sen-
sory examination and not on BSIDIII, or had missing BSIDIII scores, due to their neurological
or sensory impairment. Additionally, as far as we are aware our study was the first in its kind to
compare ASQ3 with BSIDIII at original and adjusted cut-offs at 24 months’ corrected age.
The most important weakness of our study was that we did not administer the language
scale of BSIDIII, thus hindering comparison with other studies. Adding the BSID III language
scale might have improved specificity and positive predictive value of the ASQ3 as 25% of the
children with ASQ failure without NDI failed on the ASQ communication domain (S5 Table).
Another weakness was using U.S. cut-off scores for ASQ3 and BSIDIII, because Dutch cut-off
scores were not yet available for these tools. But even so, using US cutoffs for both measures
might reduce error. Finally, even with adjusted thresholds, only 7% of all children (born before
32 weeks of gestation) had NDI, thus limiting the power of our study. Our subgroup of children
born before 28 weeks of gestation was relatively small (n = 61) and the rate of NDI was not
much higher (8%); consequently ASQ3 performed not substantially better (S3 Table).
Our results suggest that the ASQ3 is a useful developmental screening tool to help detect
NDI. Failure on ASQ3 requires to be followed by formal neurodevelopmental assessment
including BSIDIII. This approach could have important implications. It reduces the workload
and is more cost-effective since smaller groups of high-risk children are selected, who require
in-depth assessment. Available resources could thus be transferred to benefit larger groups of
high-risk children for whom neurodevelopmental testing might also be important, such as
moderate and late preterm-born children, children post-asphyxia, children with congenital
heart defects or other major congenital malformations requiring neonatal surgery.
Our findings might also encourage researchers to use this two-step approach to include,
otherwise costly developmental outcome assessments in randomized controlled trials and
cohort studies involving high-risk pregnant women and newborns. Finally, it might boost serial
ASQ use in preventive child health care in community settings and low resource settings, thus
fitting in with the policy of the American Academy of Pediatrics (AAP) to increase early detec-
tion of NDI and may help children with developmental delays to gain timely access to early
intervention services at younger age [1]. These services may include integrated developmental
support programs with physiotherapy, pre-logopedics and orthopedagogic support.
In Conclusion, this study demonstrated that ASQ3 is a simple, valid and cost-effective
screening tool to help identify and exclude NDI in very preterm-born children at the corrected
age of two years. It might be used to select those children who need more extensive neurodeve-
lopmental testing, such as BSIDIII.
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